Effects of montelukast on airway inflammation and remodeling in murine model of asthma
WANG Shaobin,SHEN Huahao
2006-01-01
Abstract:Objective To investigate the effects of early treatment of montelukast on the airway inflammation and remodeling in murine asthma model.Methods Twenty-four mice were divided into 3 groups(8 in each group) including group A[ovalbumin(OVA) sensitized/challenged mice],group B(saline sensitized/challenged mice),group C(OVA sensitized/challenged mice treated with montelukast in the early phase).Mice were sensitized on day1 and day14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling.Monterlukast(6 mg/kg) were given from the day before OVA challenge in group C.The differential counts of inflammatory cells in bronchoaveolar lavage fluids(BALF),peripheral blood(PB) as well as eosinophils(EOS) count in bone marrow(BM) were calculated.Airway inflammation indices,EOS count,amount of collagen deposition around the bronchus,area of airway smooth muscle,the degree of mucus secretion in the lumens and depth of airway smooth muscle(ASM) in bronchus of different grade were studied by HE,PAS and Masson′s staining.The supernatant collected from BALF,PB,and BM were assayed for IL-5.The BALF were also assayed for INF-γ(levels).Results In repeatedly OVA-challenged mice (group A),EOS counts in BALF,PB and BM [(45.09±4.08) ×10~4/mL,(2.41±0.31)×10~5/mL,(1.51±0.18)×10~6/femur] were increased significantly when compared with group B[(0.08±0.03)×10~4/mL,(0.62±0.09)×10~4/mL,(0.63±0.09)×10~6/femur,all P<0.01],respectively.The IL-5 levels in BALF and PB in group A increased significantly compared with group B [BALF:((57.86±)2.72) pg/mL vs (18.68±2.46) pg/mL,P<0.01;PB:(18.76±0.84) pg/mL vs(12.11±0.51) pg/mL,P<0.01] while IFN-γ in BALF decreased significantly [(36.55±1.71) pg/mL vs(64.53±5.72) pg/mL,P<0.01].EOS counts around bronchus were increased in group A [(912.12±65.97)/mm~2] when compared with group B[(8.79±2.61)/mm~2,P<0.01].Goblet cells hyperplasia [(51.12±3.50)% vs((1.92±)0.67)%,P<0.01 ]and mucus hypersecretion [score:(3.48±0.12) vs(0.17±0.08),P<0.01],airway smooth muscle hypertrophy [(25.99±0.89)μm~2/μm vs(13.06±0.60) μm~2/μm,(P<)0.01],enhanced collagen deposition of reticular basement membrane(RBM) [(29.69±2.02) μm~2/μm vs(5.56±0.35)μm~2/μm,P<0.01] were more significant in group A than those in group B.Treated with Montelukast early resulted in decreased EOS counts [(6.25±0.79)×10~4/mL in BALF,(0.71±0.11)×10~5/mL in PB and(0.77±0.10)×10~6/femur in BM],declined IL-5 levels [(25.96±1.79)pg/mL in BALF,(13.14±0.55) pg/mL in serum] and increased IFN-γ levels [(52.70±2.15)pg/mL in BALF].Montelukast also attenuated the remodeling procedure in the airway described above.Conclusions Prolonged allergen exposure could induce airway structural changes characteristic of excessive collagen deposition.Montelukast,an anti-(inflammatory) agent,has inhibitory activity on airway remodeling.